Therapeutic efficacy of carbamazepine in a HIV-1–positive patient with psoriatic erythroderma,☆☆,,★★

https://doi.org/10.1016/S0190-9622(97)80010-2Get rights and content

Abstract

J Am Acad Dermatol 1997;37:851-4.

Section snippets

CASE REPORT

A 29-year-old HIV-1–positive white man had disseminated varicella-zoster virus develop in 1992. At approximately the same time, the patient was treated for plaque psoriasis and initially the patient responded to topical therapy. During the next year, he had Pneumocystis pneumonia and disseminated Mycobacterium avium-intracellulare infection developed. By the end of 1994, the patient’s peripheral CD4 + T cell count was < 10/μm 3 . Soon thereafter he was having increasing problems controlling his

COMMENTS

Etretinate was considered the best initial choice for therapy of this patient, but carbamazepine was given mistakenly. Carbamazepine (5-carbamyl-5H-dibenzolazepine) is a tricyclic compound that has been used for many years in the treatment of epilepsy and other neurologic diseases. 4 Although the mechanism of action of carbamazepine is not well defined, it significantly inhibits the uptake of norepinephrine. It also appears to block a cyclic AMP–mediated calcium influx that is associated both

References (17)

There are more references available in the full text version of this article.

Cited by (10)

View all citing articles on Scopus

This article is made possible through an educational grant from the Dermatological Division, Ortho Pharmaceutical Corporation.

☆☆

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of the Navy, or the Department of Defense.

Reprint requests: Henry G. Skelton, MD, 6514 Rockhurst Road, Bethesda, MD 20817.

★★

0190-9622/97/$5.00 + 0 16/4/82785

View full text